<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100813</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1014</org_study_id>
    <secondary_id>2014-000037-23</secondary_id>
    <nct_id>NCT02100813</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis</brief_title>
  <official_title>Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two
      consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily
      treatment for two consecutive days compared to vehicle
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Dose Limiting Toxicity up to and including Day 8</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Reduction in AK count</measure>
    <time_frame>From baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Complete clearance of AKs</measure>
    <time_frame>At Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Partial clearance of AKs</measure>
    <time_frame>Week 8</time_frame>
    <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Part 1: LEO 43204</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label, dose escalation, 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 x dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>X dose for 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 Y dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Y dose for 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 2 days treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204</intervention_name>
    <arm_group_label>Part 1: LEO 43204</arm_group_label>
    <arm_group_label>Part 2: LEO 43204 x dose</arm_group_label>
    <arm_group_label>Part 2: LEO 43204 Y dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full
             balding scalp.

          -  Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full
             balding scalp

        Exclusion Criteria:

          -  Location of the treatment area

               -  within 5 cm of an incompletely healed wound

               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma
                  (SCC)

          -  Prior treatment with ingenol mebutate gel on the treatment area

          -  Lesions in the treatment areas that have

               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous
                  horns) and/or

               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous
                  occasions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gwinnett Clinical Research Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center, Inc.</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <disposition_first_submitted>February 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 14, 2016</disposition_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

